These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30877679)

  • 41. Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB.
    Budroni S; Kleinschmidt A; Boucher P; Medini D
    Vaccine; 2016 May; 34(23):2579-84. PubMed ID: 27083425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Understanding immunogenicity assessments for meningococcal serogroup B vaccines.
    Balmer P; Beeslaar J; Findlow J; Srivastava A
    Postgrad Med; 2020 Mar; 132(2):184-191. PubMed ID: 32124678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
    Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
    Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
    Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M
    Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: Lessons of the Normandy campaign.
    Sevestre J; Hong E; Delbos V; Terrade A; Mallet E; Deghmane AE; Lemée L; Taha MK; Caron F
    Vaccine; 2017 Jul; 35(32):4029-4033. PubMed ID: 28624305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine.
    Boccadifuoco G; Brunelli B; Pizza MG; Giuliani MM
    J Prev Med Hyg; 2012 Jun; 53(2):56-60. PubMed ID: 23240161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic Features of a Representative Panel of 110 Meningococcal B Isolates to Assess the Efficacy of Meningococcal B Vaccines.
    Muzzi A; Bodini M; Topaz N; Masignani V; Vadivelu K; Marjuki H; Wang X; Serino L; Medini D
    mSphere; 2022 Oct; 7(5):e0038522. PubMed ID: 36129279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine.
    Fagnocchi L; Biolchi A; Ferlicca F; Boccadifuoco G; Brunelli B; Brier S; Norais N; Chiarot E; Bensi G; Kroll JS; Pizza M; Donnelly J; Giuliani MM; Delany I
    Infect Immun; 2013 Feb; 81(2):560-9. PubMed ID: 23230289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.
    Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P
    Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Temporal Changes in BEXSERO® Antigen Sequence Type Associated with Genetic Lineages of Neisseria meningitidis over a 15-Year Period in Western Australia.
    Mowlaboccus S; Perkins TT; Smith H; Sloots T; Tozer S; Prempeh LJ; Tay CY; Peters F; Speers D; Keil AD; Kahler CM
    PLoS One; 2016; 11(6):e0158315. PubMed ID: 27355628
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.
    Partridge E; Lujan E; Giuntini S; Vu DM; Granoff DM
    Vaccine; 2017 Jul; 35(33):4236-4244. PubMed ID: 28651840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence and genetic characteristics of 4CMenB and rLP2086 vaccine candidates among Neisseria meningitidis serogroup B strains, China.
    Zhu B; Shi F; Zhang A; Sun X; Xu Z; Xu L; Gao Y; Lv J; Shao Z
    Vaccine; 2018 Apr; 36(15):1983-1989. PubMed ID: 29523451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
    Findlow J; Nuttens C; Kriz P
    Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them.
    Holst J
    Hum Vaccin; 2007; 3(6):290-4. PubMed ID: 17712231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.
    Masignani V; Pizza M; Moxon ER
    Front Immunol; 2019; 10():751. PubMed ID: 31040844
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands.
    Freudenburg-de Graaf W; Knol MJ; van der Ende A
    Vaccine; 2020 Nov; 38(49):7850-7857. PubMed ID: 33097311
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
    Ostergaard L; Vesikari T; Absalon J; Beeslaar J; Ward BJ; Senders S; Eiden JJ; Jansen KU; Anderson AS; York LJ; Jones TR; Harris SL; O'Neill R; Radley D; Maansson R; Prégaldien JL; Ginis J; Staerke NB; Perez JL;
    N Engl J Med; 2017 Dec; 377(24):2349-2362. PubMed ID: 29236639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.